Home > Research > Publications & Outputs > Evaluation of a sequential global test of impro...
View graph of relations

Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Published

Standard

Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. / Bolland, Kim; Whitehead, John; Cobo, Erik et al.
In: Pharmaceutical Statistics, Vol. 8, No. 2, 04.2009, p. 136-149.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

APA

Vancouver

Bolland K, Whitehead J, Cobo E, Secades JJ. Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. Pharmaceutical Statistics. 2009 Apr;8(2):136-149. doi: 10.1002/pst.344

Author

Bolland, Kim ; Whitehead, John ; Cobo, Erik et al. / Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline. In: Pharmaceutical Statistics. 2009 ; Vol. 8, No. 2. pp. 136-149.

Bibtex

@article{12a7753100ad4a9e9f17a26b7fd09ae0,
title = "Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.",
abstract = "Two-stage designs offer substantial advantages for early phase II studies. The interim analysis following the first stage allows the study to be stopped for futility, or more positively, it might lead to early progression to the trials needed for late phase II and phase III. If the study is to continue to its second stage, then there is an opportunity for a revision of the total sample size. Two-stage designs have been implemented widely in oncology studies in which there is a single treatment arm and patient responses are binary. In this paper the case of two-arm comparative studies in which responses are quantitative is considered. This setting is common in therapeutic areas other than oncology. It will be assumed that observations are normally distributed, but that there is some doubt concerning their standard deviation, motivating the need for sample size review. The work reported has been motivated by a study in diabetic neuropathic pain, and the development of the design for that trial is described in detail.",
keywords = "adaptive design • phase II trial • sample size review • sequential analysis • two-stage design",
author = "Kim Bolland and John Whitehead and Erik Cobo and Secades, {Julio J.}",
year = "2009",
month = apr,
doi = "10.1002/pst.344",
language = "English",
volume = "8",
pages = "136--149",
journal = "Pharmaceutical Statistics",
issn = "1539-1604",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

RIS

TY - JOUR

T1 - Evaluation of a sequential global test of improved recovery following stroke as applied to the ICTUS trial of citicoline.

AU - Bolland, Kim

AU - Whitehead, John

AU - Cobo, Erik

AU - Secades, Julio J.

PY - 2009/4

Y1 - 2009/4

N2 - Two-stage designs offer substantial advantages for early phase II studies. The interim analysis following the first stage allows the study to be stopped for futility, or more positively, it might lead to early progression to the trials needed for late phase II and phase III. If the study is to continue to its second stage, then there is an opportunity for a revision of the total sample size. Two-stage designs have been implemented widely in oncology studies in which there is a single treatment arm and patient responses are binary. In this paper the case of two-arm comparative studies in which responses are quantitative is considered. This setting is common in therapeutic areas other than oncology. It will be assumed that observations are normally distributed, but that there is some doubt concerning their standard deviation, motivating the need for sample size review. The work reported has been motivated by a study in diabetic neuropathic pain, and the development of the design for that trial is described in detail.

AB - Two-stage designs offer substantial advantages for early phase II studies. The interim analysis following the first stage allows the study to be stopped for futility, or more positively, it might lead to early progression to the trials needed for late phase II and phase III. If the study is to continue to its second stage, then there is an opportunity for a revision of the total sample size. Two-stage designs have been implemented widely in oncology studies in which there is a single treatment arm and patient responses are binary. In this paper the case of two-arm comparative studies in which responses are quantitative is considered. This setting is common in therapeutic areas other than oncology. It will be assumed that observations are normally distributed, but that there is some doubt concerning their standard deviation, motivating the need for sample size review. The work reported has been motivated by a study in diabetic neuropathic pain, and the development of the design for that trial is described in detail.

KW - adaptive design • phase II trial • sample size review • sequential analysis • two-stage design

U2 - 10.1002/pst.344

DO - 10.1002/pst.344

M3 - Journal article

VL - 8

SP - 136

EP - 149

JO - Pharmaceutical Statistics

JF - Pharmaceutical Statistics

SN - 1539-1604

IS - 2

ER -